HK Stock Market Move | WUXI XDC (02268) rose over 7% after performance results, with net profit for the year 25 increasing CRDMO business continues to show strong momentum.

WUXI XDC (02268) rose by over 7% after performance data released, rising by 6.5% to HK$54.15 as of the time of writing, with a trading volume of HK$3376.02 million. On the news front, on March 23, WUXI XDC announced its 2025 performance, with revenue of approximately HK$5.944 billion, a year-on-year increase of 46.7%; gross profit of approximately HK$2.139 billion, a year-on-year increase of 72.5%; adjusted net profit attributable to owners of the company of approximately HK$1.559 billion, a year-on-year increase of 69.9%; and a year-on-year increase in net profit of 38.4% to HK$1.48 billion. The total number of outstanding orders for the group also increased by 50.3% from US$991 million as of December 31, 2024, to US$1.489 billion as of December 31, 2025. The announcement stated that the group's CRDMO business has continued to show strong momentum in 2024 and 2025, with business expansion and increasing demand for its services from global clients. As of December 31, 2025, with its comprehensive CRDMO capabilities and facilities equipped with "one-stop" functionality from drug discovery to commercialization, the group has empowered a total of 643 clients globally by providing integrated services. The group has successfully obtained 18 PPQ (Process Validation) projects and 1 commercialization project.